Preclinical and Clinical Studies with the Multi-Kinase Inhibitor CEP-701 as Treatment for Prostate Cancer Demonstrate the Inadequacy of PSA Response as a Primary Endpoint

PURPOSE: CEP-701 is a potent inhibitor of trk receptors that causes cell death in prostate cancer (PC) models. CEP-701 binds to serum proteins and a preprostatectomy study was performed to assess prostate tissue penetration and clinical response to CEP-701. METHODS: Growth assays and Western blot an...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Collins, Connie, Carducci, Michael A., Eisenberger, Mario A., Isaacs, John T., Partin, Alan W., Pili, Roberto, Sinibaldi, Victoria J., Walczak, Janet S., Denmeade, Samuel R.
Formato: Artigo
Idioma:Inglês
Publicado: 2007
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4124640/
https://ncbi.nlm.nih.gov/pubmed/17786033
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares